Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) Insider Sells 1,000 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) insider Patrick J. Haley sold 1,000 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $20.23, for a total value of $20,230.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Patrick J. Haley also recently made the following trade(s):

  • On Friday, May 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $19.58, for a total value of $19,580.00.
  • On Wednesday, April 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $24.04, for a total value of $24,040.00.
  • On Tuesday, March 26th, Patrick J. Haley sold 2,700 shares of Exelixis stock. The shares were sold at an average price of $23.47, for a total value of $63,369.00.
  • On Thursday, March 14th, Patrick J. Haley sold 2,000 shares of Exelixis stock. The shares were sold at an average price of $25.00, for a total value of $50,000.00.

Shares of EXEL stock traded up $0.06 on Wednesday, reaching $20.05. The stock had a trading volume of 1,254,732 shares, compared to its average volume of 3,505,610. The company has a market cap of $6.00 billion, a P/E ratio of 14.02, a price-to-earnings-growth ratio of 0.48 and a beta of 1.98. Exelixis, Inc. has a 1 year low of $13.42 and a 1 year high of $25.31. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.56 and a quick ratio of 7.48.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.24. The firm had revenue of $215.49 million for the quarter, compared to the consensus estimate of $206.06 million. Exelixis had a return on equity of 37.21% and a net margin of 75.97%. The company’s revenue for the quarter was up .8% on a year-over-year basis. During the same period last year, the business posted $0.40 EPS. As a group, analysts expect that Exelixis, Inc. will post 0.92 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in EXEL. BlackRock Inc. raised its holdings in Exelixis by 1.0% in the 1st quarter. BlackRock Inc. now owns 30,875,633 shares of the biotechnology company’s stock worth $734,839,000 after purchasing an additional 290,882 shares during the period. Vanguard Group Inc raised its holdings in Exelixis by 3.2% in the 3rd quarter. Vanguard Group Inc now owns 26,527,089 shares of the biotechnology company’s stock worth $470,060,000 after purchasing an additional 834,478 shares during the period. AQR Capital Management LLC raised its holdings in Exelixis by 46.4% in the 1st quarter. AQR Capital Management LLC now owns 15,852,556 shares of the biotechnology company’s stock worth $377,291,000 after purchasing an additional 5,021,444 shares during the period. JPMorgan Chase & Co. raised its holdings in Exelixis by 10.1% in the 1st quarter. JPMorgan Chase & Co. now owns 9,938,985 shares of the biotechnology company’s stock worth $236,548,000 after purchasing an additional 910,147 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Exelixis by 61.6% in the 1st quarter. Renaissance Technologies LLC now owns 9,565,273 shares of the biotechnology company’s stock worth $227,653,000 after purchasing an additional 3,645,546 shares during the period. Hedge funds and other institutional investors own 78.27% of the company’s stock.

Several analysts have commented on EXEL shares. Cowen reiterated a “buy” rating and set a $29.00 target price on shares of Exelixis in a research note on Tuesday, April 23rd. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. Oppenheimer restated a “buy” rating on shares of Exelixis in a research note on Tuesday, March 19th. Morgan Stanley upgraded Exelixis from an “underweight” rating to an “equal weight” rating and set a $24.80 price target on the stock in a research note on Monday, March 18th. Finally, ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a research note on Wednesday, March 6th. Six equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Exelixis presently has an average rating of “Buy” and a consensus target price of $28.88.

COPYRIGHT VIOLATION WARNING: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2019/06/12/insider-selling-exelixis-inc-nasdaqexel-insider-sells-1000-shares-of-stock.html.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

See Also: How to Use the New Google Finance Tool

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply